Anne-Sophie de Faucigny
Public Communications Contact bij GETLINK SE
Profiel
Anne-Sophie de Faucigny is currently the Group Chief Communication Officer at Getlink SE.
Previously, she worked as the Director at Yposkesi from 2018 to 2021.
She is a graduate of Institut d’Études Politiques de Toulouse.
Actieve functies van Anne-Sophie de Faucigny
| Bedrijven | Functie | Begin |
|---|---|---|
| GETLINK SE | Public Communications Contact | 01-10-2022 |
Eerdere bekende functies van Anne-Sophie de Faucigny
| Bedrijven | Functie | Einde |
|---|---|---|
Yposkesi
 Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Director/Board Member | 01-01-2021 |
Opleiding van Anne-Sophie de Faucigny
| Institut d’Études Politiques de Toulouse | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| GETLINK SE | Transportation |
| Bedrijven in privébezit | 1 |
|---|---|
Yposkesi
Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The private company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021. | Health Technology |
